Gilead Completes HCV Clinical Development With Vosevi Approval

Bringing three-drug, single-tablet regimen to market means Gilead has an answer for every hepatitis C patient, company says. It still lacks an answer, however, for its future business direction as HCV revenue wanes.

Gilead Sciences Inc. obtained US approval – about three weeks ahead of an Aug. 8 user fee date – for its final hepatitis C product incorporating the nucleoside polymerase inhibitor sofosbuvir as the US FDA okayed Vosevi (sofosbuvir/velpatasvir/voxilaprevir) July 18 as a treatment for HCV-infected patients who have failed prior therapy with a direct-acting antiviral regimen.

With the Foster City, Calif.-based firm earlier this year slashing sales guidance for its HCV franchise, the Vosevi approval can...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip